Trials / Conditions / Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
3 registered clinical trials studyying Resectable Hepatocellular Carcinoma With High Risk of Recurrence — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for H NCT07239245 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of NCT06954116 | Tongji Hospital | Phase 2 |
| Recruiting | The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) NCT07064681 | Sun Yat-sen University | — |